| Identification | Back Directory | [Name]
Sarpogrelate | [CAS]
125926-17-2 | [Synonyms]
Sapogrelate
SARPOGRELATE
Sarpogrelate USP/EP/BP
(+/-)-2-(dimethylamino)-1-{(o-(m-methoxyphenethyl)phenoxy)methyl}ethyl hydrogen succinate
4-[1-(dimethylaminomethyl)-2-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]ethoxy]-4-keto-butyric acid
4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxobutanoic acid
4-[1-(dimethylamino)-3-[2-[2-(3-methoxyphenyl)ethyl]phenoxy]propan-2-yl]oxy-4-oxo-butanoic acid
Butanedioic acid, 1-[2-(diMethylaMino)-1-[[2-[2-(3-Methoxyphenyl)ethyl]phenoxy]Methyl]ethyl] ester
Butanedioic acid, mono[2-(dimethylamino)-1-[[2-[2-(3-methoxyphenyl)ethyl]phenoxy]methyl]ethyl] ester (9CI) | [Molecular Formula]
C24H31NO6 | [MDL Number]
MFCD00866779 | [MOL File]
125926-17-2.mol | [Molecular Weight]
429.51 |
| Hazard Information | Back Directory | [Uses]
Sarpogrelate (MCI-9042) is a new, specific orally active 5-HT2 receptor antagonist, Sarpogrelate increases platelet aggregation and has hemostasis effect, and can be used for the research of Buerger’s disease[1]. | [Definition]
ChEBI: Sarpogrelate is a stilbenoid and a hemisuccinate. | [IC 50]
5-HT2 Receptor | [References]
[1] A Rydzewski, et al. The effect of a 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res. 1996 Dec 15;84(6):445-52. DOI:10.1016/s0049-3848(96)00212-5 |
|
|